NASDAQ, ACAD - Acadia Pharmaceutica
We are a biopharmaceutical company focused on the discovery, development, and
commercialization of small molecule drugs for the treatment of central nervous
system disorders. We currently have six clinical programs and several additional
programs in discovery and development. In our most advanced program, we are
conducting Phase III studies with pimavanserin for the treatment of Parkinson?s
disease psychosis. We have reported positive results from a Phase II trial in
our program with pimavanserin as a co-therapy in schizophrenia. We also have
completed enrollment of a Phase IIb trial in our program with ACP-104 as a
stand-alone treatment for schizophrenia. In addition, we have completed a
proof-of-concept clinical study with pimavanserin for the treatment of sleep
maintenance insomnia in healthy older adults. We have retained worldwide
commercialization rights for our programs with pimavanserin and ACP-104. ...
Read SEC Filing on NASDAQ.com »